H.C. Wainwright raised the firm’s price target on CymaBay to $24 from $21 and keeps a Buy rating on the shares post the Q3 report. The analyst expects seladelpar’s U.S. approval around early 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY:
- CymaBay reports Q3 EPS (32c), consensus (30c)
- Is CBAY a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today
- CymaBay announces publication of safety, efficacy results of seladelpar
- CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023